Investor & News

Share Information:

ROS Therapeutics ApS is a privately held company, operating under the CVR number 39507501

Stock Information:

Number of shares: 81,565
Nominal value per share: DKK 1

Share capital: DKK 81,565

Shareholders holding more than 5% of the shares:

ROS Therapeutics Holding ApS

INNOVATIONS A/S

Rasmus Wilhelmsen

Principal Law Firm:

Bach Advokater / Ricki Boye

Key dates:

Founded: 23rd of April, 2018

Most recent capital increase: 12th of July, 2018

Most recent Annual General Meeting: Not applicable

Financial Calendar year-end: 31 December

NEWS

A New targeted MTX underway for RA

2018-11-11

Health Europa Quarterly (issue 07) highlights the advantages and disadvantages of the currently recommended first-line treatment for rheumatoid arthritis and reflects on recent research into a possible alternative: A new targeted-MTX treatment underway for rheumatoid arthritis

READ

ROS Therapeutics™ raises DKK 10 million in seed financing round

2018-07-13

ROS Therapeutics today announces the successful closing of a DKK 10.1 mill. seed financing round with participation of founders, advisors, business angels and other private investors.

READ

ROS Therapeutics™ signs patent license agreement

2018-07-03

ROS Therapeutics™ signs patent license agreement with the Technical University of Denmark (DTU) regarding molecules for the treatment of inflammatory diseases and cancer

READ